Abstract
TALAPRO-1 enrolled men with progressive mCRPC and tumor DDRm involved either directly or indirectly in homologous recombination repair (HRR) (11-gene panel). These men had received 1–2 taxane-based chemotherapy and progressed on ≥1 novel hormonal therapy. The primary endpoint was objective response rate ([ORR] per RECIST v.1.1; central review). Exploratory ad hoc biomarker analyses assessed non-DDR/HRR mutational landscape and associations with antitumor activity.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
